Protocol Ledger

NCT04534205 · Phase II/III · ACTIVE NOT RECRUITING

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human

Interventional Phase II/III clinical trial protocol NCT04534205 sponsored by BioNTech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-07 Enrollment: 358 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04534205
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)358 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04534205
Protocol FieldVerified Registry Value
NCT IdentifierNCT04534205
Consolidated Lead SponsorBioNTech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment358 participants (ACTUAL)
Registered Start Date2021-01-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI